Environmental Alterations in Biofuel Generating Molecules in Zilla Spinosa
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Retention Indices for Frequently Reported Compounds of Plant Essential Oils
Retention Indices for Frequently Reported Compounds of Plant Essential Oils V. I. Babushok,a) P. J. Linstrom, and I. G. Zenkevichb) National Institute of Standards and Technology, Gaithersburg, Maryland 20899, USA (Received 1 August 2011; accepted 27 September 2011; published online 29 November 2011) Gas chromatographic retention indices were evaluated for 505 frequently reported plant essential oil components using a large retention index database. Retention data are presented for three types of commonly used stationary phases: dimethyl silicone (nonpolar), dimethyl sili- cone with 5% phenyl groups (slightly polar), and polyethylene glycol (polar) stationary phases. The evaluations are based on the treatment of multiple measurements with the number of data records ranging from about 5 to 800 per compound. Data analysis was limited to temperature programmed conditions. The data reported include the average and median values of retention index with standard deviations and confidence intervals. VC 2011 by the U.S. Secretary of Commerce on behalf of the United States. All rights reserved. [doi:10.1063/1.3653552] Key words: essential oils; gas chromatography; Kova´ts indices; linear indices; retention indices; identification; flavor; olfaction. CONTENTS 1. Introduction The practical applications of plant essential oils are very 1. Introduction................................ 1 diverse. They are used for the production of food, drugs, per- fumes, aromatherapy, and many other applications.1–4 The 2. Retention Indices ........................... 2 need for identification of essential oil components ranges 3. Retention Data Presentation and Discussion . 2 from product quality control to basic research. The identifi- 4. Summary.................................. 45 cation of unknown compounds remains a complex problem, in spite of great progress made in analytical techniques over 5. -
(12) United States Patent (10) Patent No.: US 9,375.433 B2 Dilly Et Al
US009375433B2 (12) United States Patent (10) Patent No.: US 9,375.433 B2 Dilly et al. (45) Date of Patent: *Jun. 28, 2016 (54) MODULATORS OF ANDROGENSYNTHESIS (52) U.S. Cl. CPC ............. A6 IK3I/519 (2013.01); A61 K3I/201 (71) Applicant: Tangent Reprofiling Limited, London (2013.01); A61 K3I/202 (2013.01); A61 K (GB) 31/454 (2013.01); A61K 45/06 (2013.01) (72) Inventors: Suzanne Dilly, Oxfordshire (GB); (58) Field of Classification Search Gregory Stoloff, London (GB); Paul USPC .................................. 514/258,378,379, 560 Taylor, London (GB) See application file for complete search history. (73) Assignee: Tangent Reprofiling Limited, London (56) References Cited (GB) U.S. PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this 5,364,866 A * 1 1/1994 Strupczewski.......... CO7C 45/45 patent is extended or adjusted under 35 514,254.04 U.S.C. 154(b) by 0 days. 5,494.908 A * 2/1996 O’Malley ............. CO7D 261/20 514,228.2 This patent is Subject to a terminal dis 5,776,963 A * 7/1998 Strupczewski.......... CO7C 45/45 claimer. 514,217 6,977.271 B1* 12/2005 Ip ........................... A61K 31, 20 (21) Appl. No.: 14/708,052 514,560 OTHER PUBLICATIONS (22) Filed: May 8, 2015 Calabresi and Chabner (Goodman & Gilman's The Pharmacological (65) Prior Publication Data Basis of Therapeutics, 10th ed., 2001).* US 2015/O238491 A1 Aug. 27, 2015 (Cecil's Textbook of Medicine pp. 1060-1074 published 2000).* Stedman's Medical Dictionary (21st Edition, Published 2000).* Okamoto et al (Journal of Pain and Symptom Management vol. -
Fatty Acids As Essential Adjuvants to Treat Various Ailments and Their Role in Drug Delivery: a Review
Nutrition 65 (2019) 138À157 Contents lists available at ScienceDirect Nutrition journal homepage: www.nutritionjrnl.com Review article Fatty acids as essential adjuvants to treat various ailments and their role in drug delivery: A review Aakash Katdare B. Pharm, MS. Pharm, Shreya Thakkar B. Pharm, M. Pharm, Shivshankar Dhepale B. Pharm, MS. Pharm, Dignesh Khunt B. Pharm, M. Pharm, Manju Misra B. Pharm, M. Pharm, Ph.D. * Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Ahmedabad, India ARTICLE INFO ABSTRACT Article History: Since the discovery of fatty acids, a niche has been carved for their vital role as adjuvants in drug delivery and Received 23 May 2018 as treatment for various diseases. The literature has repeatedly described the essential role of various fatty Received in revised form 1 February 2019 acids in treating a wide range of diseases and disorders, from central nervous system diseases to wound heal- Accepted 20 March 2019 ing. The use of fatty acids has expanded to many horizons and in recent decades they have gained impor- tance as drug delivery adjuvants in addition to their auxiliary benefits in treating various diseases. Although Keywords: fatty acids aid in solving both formulation-based and therapeutic challenges to our knowledge, they have Polyunsaturated FA never been viewed as dual agents in modern scientific literature. The aim of this review was to provide this FA Lipids perspective and combine the very discreet literature about fatty acids, which includes their role as therapeu- Oils tic adjuvants and drug delivery agents. It gives insights on the use of fatty acids in treating the diseases of the Penetration enhancers eye, skin, central nervous system, viral diseases, and so on. -
Biochemistry Prologue to Lipids
Paper : 05 Metabolism of Lipids Module: 01 Prologue to Lipids Principal Investigator Dr. Sunil Kumar Khare, Professor, Department of Chemistry, IIT-Delhi Paper Coordinator and Dr. Suaib Luqman, Scientist (CSIR-CIMAP) Content Writer & Assistant Professor (AcSIR) CSIRDr. Vijaya-CIMAP, Khader Lucknow Dr. MC Varadaraj Content Reviewer Prof. Prashant Mishra, Professor, Department of Biochemical Engineering and Biotechnology, IIT-Delhi 1 METABOLISM OF LIPIDS Biochemistry Prologue to Lipids DESCRIPTION OF MODULE Subject Name Biochemistry Paper Name 05 Metabolism of Lipids Module Name/Title 01 Prologue to Lipids 2 METABOLISM OF LIPIDS Biochemistry Prologue to Lipids 1. Objectives To understand what is lipid Why they are important How they occur in nature 2. Concept Map LIPIDS Fatty Acids Glycerol 3. Description 3.1 Prologue to Lipids In 1943, the term lipid was first used by BLOOR, a German biochemist. Lipids are heterogeneous group of compounds present in plants and animal tissues related either actually or potentially to the fatty acids. They are amphipathic molecules, hydrophobic in nature originated utterly or in part by thioesters (carbanion-based condensations of fatty acids and/or polyketides etc) or by isoprene units (carbocation-based condensations of prenols, sterols, etc). Lipids have the universal property of being: i. Quite insoluble in water (polar solvent) ii. Soluble in benzene, chloroform, ether (non-polar solvent) 3 METABOLISM OF LIPIDS Biochemistry Prologue to Lipids Thus, lipids include oils, fats, waxes, steroids, vitamins (A, D, E and K) and related compounds, such as phospholipids, triglycerides, diglycerides, monoglycerides and others, which are allied more by their physical properties than by their chemical assests. -
Measurement of Attenuation Cross-Sections of Some Fatty Acids in the Energy Range 122–1330 Kev
Pramana – J. Phys. (2016) 87: 12 c Indian Academy of Sciences DOI 10.1007/s12043-016-1213-y Measurement of attenuation cross-sections of some fatty acids in the energy range 122–1330 keV D K GAIKWAD1,∗,PPPAWAR1 and T P SELVAM2 1Department of Physics, Dr Babasaheb Ambedkar Marathwada University, Aurangabad 431 004, India 2Radiation Physics and Advisory Division, BARC, Anushaktinagar, Mumbai 400 085, India ∗Corresponding author. E-mail: [email protected] MS received 14 June 2015; revised 7 August 2015; accepted 7 September 2015; published online 18 June 2016 Abstract. The mass attenuation coefficients (μm) have been measured for undecylic acid (C11H22O2), lau- ric acid (C12H24O2), tridecylic acid (C13H26O2), myristic acid (C14H28O2), pentadecylic acid (C15H30O2)and 57 133 137 60 22 palmitic acid (C16H32O2)using Co, Ba, Cs, Co and Na emitted γ radiation with energies 122, 356, 511, 662, 1170, 1275 and 1330 keV, respectively. The accurate values of the effective atomic number (Zeff), atomic cross-section (σt,), electronic cross-section (σe) and the effective electron density (Neff) have great signifi- cance in radiation protection and dosimetry. These quantities were obtained by utilizing experimentally measured values of mass attenuation coefficients (μm). A NaI(Tl) scintillation detector with 8.2% (at 662 keV) resolu- tion was used for detecting of attenuated γ -photons. The variation in Zeff and Neff of fatty acids with energy is discussed. The experimental and theoretical results are in good agreement within 2% deviation. Keywords. Fatty acids; NaI(Tl) scintillation detector; Zeff and Neff. PACS Nos 32.80.−t; 32.90.+a; 32.80.Fb; 20; 33.80.−b 1. -
NON-CLINICAL REVIEW(S) DEPARTMENT of HEALTH & HUMAN SERVICES Food and Drug Administration
CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 206089Orig1s000 NON-CLINICAL REVIEW(S) DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration PHARMACOLOGY/TOXICOLOGY MEMORANDUM CDER Stamp Date: September 27, 2018 NDA: 206089 Sponsor: Clarus Therapeutics, Inc. Drug: Testosterone undecanoate (JATENZO) Replacement therapy in adult males for conditions associated Indication: with a deficiency or absence of endogenous testosterone due to primary or hypogonadotropic hypogonadism Subject: Final Labeling Review Reviewer: Yangmee Shin, PhD Background: Clarus Therapeutics resubmitted NDA 206089 under a 505(b)(2) regulatory pathway following a 2nd Complete Response (CR) letter issued on March 22, 2018. NDA 206089 was first submitted on January 3, 2014 as a 505(b)(2) application. To support the nonclinical requirements of NDA via a 505(b)(2) pathway, the sponsor submitted published literature along with the findings of a 3-month oral toxicology study of Clarus’ oral testosterone undecanoate (TU) formulation in dogs. The sponsor also provided literature references to address ADME of TU by the oral route. The 3-month oral toxicology study in male dogs and relevant published literature were provided to support the use of borage oil as a novel excipient. The sponsor also supplied published literature regarding the fertility, pregnancy, and carcinogenicity of testosterone (T). Pharmacology and Toxicology recommended approval of the initial submission of NDA 206089 during the first cycle review. In the 1st resubmission to NDA 206089 on June 22, 2017, Clarus refiled the NDA as a 505(b)(1) application and provided nonclinical studies of oral TU including a 9-month oral toxicology study in male dogs, a battery of genotoxicity tests, a 6-month carcinogenicity study in Tg·rasH2 male mice, and a fertility study in male rats, upon agreement with the Division on November 19, 2015. -
Fatty Acids, Trivial and Systematic Names
FATTY ACIDS, TRIVIAL AND SYSTEMATIC NAMES Trivial Name Systematic Name Abbreviation Formic Acid Methanoic Acid Acetic Acid Ethanoic Acid Propionic Acid Propanoic Acid Butyric Acid Butanoic Acid 4:0 Valerianic Acid Pentanoic Acid 5:0 Caproic Acid Hexanoic Acid 6:0 Enanthic Acid Heptanoic Acid 7:0 Caprylic Acid Octanoic Acid 8:0 Pelargonic Acid Nonanoic Acid 9:0 Capric Acid Decanoic Acid 10:0 Obtusilic Acid 4-Decenoic Acid 10:1(n-6) Caproleic Acid 9-Decenoic Acid 10:1(n-1) Undecylic Acid Undecanoic Acid 11:0 Lauric Acid Dodecanoic Acid 12:0 Linderic Acid 4-Dodecenoic Acid 12:1(n-8) Denticetic Acid 5-Dodecenoic Acid 12:1(n-7) Lauroleic Acid 9-Dodecenoic Acid 12:1(n-3) Tridecylic Acid Tridecanoic Acid 13:0 Myristic Acid Tetradecanoic Acid 14:0 Tsuzuic Acid 4-Tetradecenoic Acid 14:1(n-10) Physeteric Acid 5-Tetradecenoic Acid 14:1(n-9) Myristoleic Acid 9-Tetradecenoic Acid 14:1(n-5) Pentadecylic Acid Pentadecanoic Acid 15:0 Palmitic Acid Hexadecanoic Acid 16:0 Gaidic acid 2-Hexadecenoic Acid 16:1(n-14) Sapienic Acid 6-Hexadecenoic Acid 16:1(n-10) Hypogeic Acid trans-7-Hexadecenoic Acid t16:1(n-9) cis-Hypogeic Acid 7-Hexadecenoic Acid 16:1(n-9) Palmitoleic Acid 9-Hexadecenoic Acid 16:1(n-7) Palmitelaidic Acid trans-9-Hexadecenoic Acid t16:1(n-7) Palmitvaccenic Acid 11-Hexadecenoic Acid 16:1(n-5) Margaric Acid Heptadecanoic Acid 17:0 Civetic Acid 8-Heptadecenoic Acid 17:1 Stearic Acid Octadecanoic Acid 18:0 Petroselinic Acid 6-Octadecenoic Acid 18:1(n-12) Oleic Acid 9-Octadecenoic Acid 18:1(n-9) Elaidic Acid trans-9-Octadecenoic acid t18:1(n-9) -
Man Hon. Tsang Oakland, CA (US); E E SE, 9
USOO81831 89B2 (12) United States Patent (10) Patent No.: US 8,183,189 B2 Chen et al. (45) Date of Patent: May 22, 2012 (54) PREPARATION OF A SULFURIZED 3,509,051 A 4, 1970 Farmer et al. MOLYBDENUMAMIDE COMPLEX AND 4,098,705. A 7/1978 Sakurai et al. 4,259,194 A 3, 1981 deVries et al. ADDITIVE COMPOSITIONS HAVINGLOW 4,259,195 A 3/1981 King et al. RESIDUAL ACTIVE SULFUR 4.261,843 A 4/1981 King et al. 4,263,152 A 4, 1981 King et al. (75) Inventors: Quinlai Chen, Walnut Creek, CA (US); 4,289,635 A 9, 1981 Schroeck Man Hon. Tsang Oakland, CA (US); E E SE,9 a. Gaurav Bhalla, Hercules, CA (US); 6,174,842 B1 1/2001 Gatto 5. William R. Ruhe, Jr., Benicia, CA (US) 6,358,894 B1 3/2002 Leta et al. 6,509,303 B1 1/2003 Gatto (73) Assignee: Chevron Oronite Company LLC, San 6,914,037 B2 7/2005 Gatto Ramon, CA (US) 2002fOO38.5256,962,896 A1B2 11/20054/2002 Ruhe,Callis etJr. al.et al. (*) Notice: Subject to any disclaimer, the term of this 38885, A. ck 239, Athlet al. ............. 508,198 patent is extended or adjusted under 35 2005/0209111 A1* 9, 2005 Ruhe et al. .................... 508/242 U.S.C. 154(b) by 191 days. OTHER PUBLICATIONS (21) Appl. No.: 12/570,974 PCT International Search Report PCT/US2009/059083 Date of mailing Jun. 18, 2010. (22) Filed: Sep. 30, 2009 * cited by examiner (65)65 PriorO PublicationDO Dat Primary Examiner – Walter D Griffin US 2011 FOOT718O A1 Mar. -
CXXVI.-Y%C Fiycld)~-Omicles of Undecylenic Acid
View Article Online / Journal Homepage / Table of Contents for this issue THE IIY DROBROMIDES OF UNDECYLENIC ACID. 1191 CXXVI.-Y%c fIycld)~-omiclesof Undecylenic Acid. By JAMES WALKERand JOHNs. LUMSDEN. BRUNNER(Bey-., 1886, 18, 2226), by the addition of hydrogen bromide to undecylenic acid, CI,H,,02, obtained a bromundecylic acid, C,,H,,O,Br, which fused at 35’. No details of the mode of preparation or purification are given. The same acid is mentioned by Nordlinger (Ber., 1890, 23, 2357), but again no details are given. Nardlinger also, by the addition of hydrogen bromide to the methyl and ethyl esters of undecylenic acid, prepared the corresponding esters of a bromundecylic acid, As it has been proved with practical certainty that ufidecylenic acid has the formula CH,:CH*[CH,],*CO,H, compounds obtained from it by the addition of hydrogen bromide must have one or other of the formula : CH,Br*CH,*[CH,],*CO,H and CH,*C€€Br*[CH,~,*CO2H. Nordlinger, on the strength of the rule that the halogen atom in such additions generally takes up the position more remote from the Published on 01 January 1901. Downloaded by Fudan University 23/11/2017 08:36:04. carboxyl group, assumes that Brunner’s acid has the formula CH,Br*[CH,]9*C0,H and that the esters which he himself prepared are the esters of this acid. Since these esters have been made the starting point for determining the constitution of various substances, it is plainly of importance to know if Nordlinger’s assumptions are justified, In the present paper, it is shown that the acid CH,Br*[CH,],*CO,H is not Brunner’s acid, which has in all probability the other con- stitution, C?H,*CHBr*[CH,],*CO,H. -
A Review of Medium-Chain Fatty Acid Production
processes Review Fermentation of Organic Residues to Beneficial Chemicals: A Review of Medium-Chain Fatty Acid Production Panagiota Stamatopoulou , Juliet Malkowski, Leandro Conrado, Kennedy Brown and Matthew Scarborough * Department of Civil and Environmental Engineering, University of Vermont, Burlington, VT 05405, USA; [email protected] (P.S.); [email protected] (J.M.); [email protected] (L.C.); [email protected] (K.B.) * Correspondence: [email protected] and [email protected] Received: 14 October 2020; Accepted: 23 November 2020; Published: 28 November 2020 Abstract: Medium-chain fatty acids (MCFAs) have a variety of uses in the production of industrial chemicals, food, and personal care products. These compounds are often produced through palm refining, but recent work has demonstrated that MCFAs can also be produced through the fermentation of complex organic substrates, including organic waste streams. While “chain elongation” offers a renewable platform for producing MCFAs, there are several limitations that need to be addressed before full-scale implementation becomes widespread. Here, we review the history of work on MCFA production by both pure and mixed cultures of fermenting organisms, and the unique metabolic features that lead to MCFA production. We also offer approaches to address the remaining challenges and increase MCFA production from renewable feedstocks. Keywords: chain elongation; carboxylate platform; medium-chain fatty acids; carboxylic acids; mixed culture fermentation 1. Introduction Microbial fermentation processes play an important role in food production, nutrient cycling, and pollution remediation. For more than 9000 years, humans have relied on microbial fermentation to produce and protect food [1], and fermentation processes have been used to convert wastes into valuable products since at least the 13th century [2]. -
United States Patent (19) 11 4,277,468 Hofmeister Et Al
United States Patent (19) 11 4,277,468 Hofmeister et al. 45 Jul. 7, 1981 (54) 11-METHYLENESTEROIDS, THEIR 56) References Cited PREPARATION AND PHARMACEUTICAL U.S. PATENT DOCUMENTS PREPARATIONS CONTAINING THEM 3,927,046 12/1975 van den Broek ................ 260/.397.45 (75) Inventors: Helmut Hofmeister; Rudolf Wiechert; OTHER PUBLICATIONS Klaus Annen; Henry Laurent; Fried et al., JACS 83 (1961), pp. 4663-4464. Hermann Steinbeck, all of Berlin, Fed. Rep. of Germany Primary Examiner-Elbert L. Roberts Attorney, Agent, or Firm-Millen & White 73) Assignee: Schering Aktiengesellschaft, Berlin 57 ABSTRACT and Bergkamen, Fed. Rep. of 11-Methylene steroids of Formula I Germany OR 21 Appl. No.: 135,066 H2Cs Sesno CECC 22 Filed: Mar. 28, 1980 (30) Foreign Application Priority Data x1a Mar. 30, 1979 DE Fed. Rep. of Germany ....... 291.338 wherein m (51) Int. Cl. ................................................ CO7 1/OO R is hydrogen or acyl, and 52 U.S. C. ............................... 424/243; 260/397.45; X is oxygen or two hydrogen atoms 260/.397.5 have valuable pharmacological properties. 58) Field of Search ............. 260/.397.4, 397.45, 397.5; 424/243 10 Claims, No Drawings 4,277,468 2 acid, isonicotinic acid, furan-2-carboxylic acid, O 11-METHYLENE STEROIDS, THEIR tridecanoylglycolic acid, O-hexadecanoylglycolic acid, PREPARATION AND PHARMACEUTICAL g-tridecanoyloxypropionic acid, etc. Suitable sulfonic PREPARATIONS CONTAINING THEM acids include: methane-, ethane-, 3-chloroethane-, pro pane-, isopropane-, butane-, cyclopentane-, cyclohex BACKGROUND OF THE INVENTION ane-, benzene-, p-toluene- and p-chlorobenzenesulfonic The present invention relates to 11-methylene ste acids, etc.; and, furthermore, N,N-dimethyl-, N,N- roids, a process for their preparation, and pharmaceuti diethyl, bis(3-chloroethyl)-aminosulfonic acids, etc.; or cal preparations containing them. -
UNITED STATES PATENT of FICE 2,345,632 POLAM DES ) Edwin A
Patented Apr. 4, 1944 2,345,632 UNITED STATES PATENT OF FICE 2,345,632 POLAM DES ) Edwin A. Robinson, Chatham, and Maurice J. Kelley, Newark, N.J., assignors to National Oil Products Company, Harrison, N.J., a corpora tion of New Jersey N. No Drawing. Application May 20, 1939, serial No. 274,808 13 Claims. (CL 260-404.5) This invention relates to textile lubricants and vide a process for the preparation of textile softeners, more particularly to textile lubricants lubricants and softeners from polyamines. and softeners comprising mixed fatty polyamides. We have now found that polyamides having It has been proposed to use higher fatty the general formula R1CO-NR3-X-COR2 in amides, such as oleic acid amide, oleic acid which R1 stands for an alkyl radical containing methyl amide and oleic acid ethylene diamide from 7 to 21 carbon atoms, Ra stands for an alkyl as Softeners and lubricants for textile materials. radical containing from 1 to 4 Carbon atoms, ER3 Such amides are ordinarily prepared by reacting stands for hydrogen or an acyl group containing a fatty acid or fatty ester with a mono- or poly from 2 to 5 carbon atoms and X stands for the amine. The reaction of monoamines with higher O grouping (CRR-CR-R-NR) , Wherein R4 fatty acids or fatty esters yields products which and R5 stand for hydrogen or alkyl radicals, and n. are not readily dispersible in water, and since is a whole number, may be applied to textile these products contain no residual amino group, materials so as to impart thereto excellent soft they may not be solubilized to any substantial ness, drape and pliability without causing yellow extent by treatment with acids.